ONCOBONE VENTURES ENTERS INTO 3 CO-OPERATION FRAMEWORK AGREEMENTS
OncoBone Ventures (www.oncoboneventures.com), a UK start-up biotech company seeking to develop novel therapies for cancer patients with currently incurable bone metastases, is pleased to announce the signing of Co-operation Framework Agreements (“Agreements”) with three partners (“Partners”), Okayama University in Japan (www.okayama-u.ac.jp), University of Bradford in UK (www.bradford.ac.uk) and The Development Center for Biotechnology (DCB) in Taiwan (www.dcb.org.tw).
The Agreements include preclinical testing of therapeutic assets developed by Partners for the treatment of cancer. The role of OncoBone Ventures will be to evaluate the efficacy of the therapeutic assets in preclinical bone metastasis models, followed by safety assessments for those assets that demonstrate good efficacy for bone metastases.
Dr. Jussi Halleen, CEO of OncoBone Ventures comments: "We are delighted to have signed these Co-operation Agreements with such prestigious institutions. The Agreements will provide a consistent basis for our future co-operation with the Partners within an agreed framework."